Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 19/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517612 | 1.00 | P2RY2 (0.57) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL11178912 | 0.89 | HPRT1 (0.53) | P2RY2P2RY6 | |
| Demannose SCHEMBL29609189 | 0.84 | P2RY2 (0.43) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL11760463 | 0.83 | P2RY2 (0.58) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL10709774 | 0.83 | P2RY2 (0.56) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL11756652 | 0.83 | P2RY2 (0.55) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL20897110 | 0.82 | P2RY2 (0.53) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL31258281 | 0.81 | P2RY2 (0.54) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL11753851 | 0.81 | CDA (0.57) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL11753918 | 0.80 | P2RY2 (0.52) | P2RY2P2RY6P2RY4P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122038302-A | Modified T cells and methods of making and using the same | 哈佛学院校长同事会 | 2026-05-15 | — | — | CN | claimed |
| US-20240327862-A1 | Methods of Treating Rheumatoid Arthritis Using RNA-Guided Genome Editing of HLA Gene | NATIONAL JEWISH HEALTH | 2024-10-03 | — | — | US | claimed |
| EP-4400175-A2 | METHODS OF TREATING RHEUMATOID ARTHRITIS USING RNA-GUIDED GENOME EDITING OF HLA GENE | The Regents of the University of Colorado, a body corporate (US) | 2024-07-17 | — | — | EP | claimed |
| EP-2981617-B1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | HARVARD COLLEGE (US) | 2023-07-05 | — | — | EP | claimed |
| CN-115261411-A | Therapeutic uses of genome editing with CRISPR/Cas systems | 哈佛学院校长同事会 | 2022-11-01 | — | — | CN | claimed |
| US-20220333119-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2022-10-20 | — | — | US | claimed |
| CN-105518146-B | Therapeutic uses of genome editing with CRISPR/Cas systems | 哈佛学院校长同事会 | 2022-07-15 | — | — | CN | claimed |
| US-20210285015-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | HARVARD COLLEGE (US) | 2021-09-16 | — | — | US | claimed |
| US-20210274726-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | HARVARD COLLEGE (US) | 2021-09-09 | — | — | US | claimed |
| US-20210277423-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | HARVARD COLLEGE (US) | 2021-09-09 | — | — | US | claimed |
| US-9822370-B2 | Method of making a deletion in a target sequence in isolated primary cells using Cas9 and two guide RNAs | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-21 | — | — | US | claimed |
| WO-2016160721-A1 | MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-10-06 | — | — | WO | claimed |
| EP-3019595-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | President and Fellows of Harvard College (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2016057821-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-04-14 | — | — | WO | claimed |
| WO-2016057835-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-04-14 | — | — | WO | claimed |
| US-20150176013-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2015-06-25 | — | — | US | claimed |
| US-20150152436-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | claimed |
| US-20150071889-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-03-12 | — | — | US | claimed |
| WO-2015006498-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-01-15 | — | — | WO | claimed |
| US-20100317005-A1 | Modified Nucleotides and Methods for Making and Use Same | Life Technologies Corporation (US) | 2010-12-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277423-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | ZFX, APOBEC3A, DCLRE1B | P2RY2 4362/4885P2RY6 4454/4885P2RY4 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.